Medico Remedies growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+36.7%+4.2%+3.2%
+13.5%+16.2%+34.2%
+16.4%+19.4%+45.4%
+29.9%+21.7%+14.5%
+29.5%+22.0%+14.9%
+28.2%+24.4%+10.0%
+21.2%+18.9%+19.5%
+20.1%+100.7%−70.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹18.98

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹158 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+3.2+4.2+36.7—
EBITDA Growth—+34.2+16.2+13.5—
EBIT Growth—+45.4+19.4+16.4—
Net Income Growth—+14.5+21.7+29.9—
EPS Growth—+14.9+22.0+29.5—
Total Assets Growth—+10.0+24.4+28.2—
Total Equity Growth—+19.5+18.9+21.2—
Cash from Operations Growth—-70.1+100.7+20.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.